Clinical trials, industrial property or human factor engineering will be key topics to be discussed with the students.
The Valdecilla Health Research Institute (IDIVAL) participates in the Master’s Degree in Health Services Management of the University of Cantabria (UC), whose objective is to train professionals capable of leading processes of change and innovation in health systems.
The postgraduate course is made up of seven different modules and IDIVAL leads the block focused on health research within the module ‘Health Research. Public Health’. Classes will be held from February 16 to March 1 on a wide variety of topics.
Firstly, IDIVAL will talk about human factor engineering and medical technologies showing their current relevance in the bio-health field. The block will continue to delve into the role of scientific-technical platforms within health institutes, research with human biological samples and the role of hospital biobanks. Clinical trials will also be a key topic to be dealt with by Valdecilla’s Clinical Trials Unit, which will detail the steps involved in managing the clinical trial approval process and the necessary contracts.
The IDIVAL Management Department will also explain the IDIVAL model, the framework and sources of funding, as well as the institute’s research and innovation management. It will also address the national science and technology strategy, health innovation strategies and the strategic plan of a health research institute such as IDIVAL.
With regard to scientific activity, there will be a discussion on its evaluation, the good clinical practices that are necessary, in addition to dealing with concepts such as innovation and industrial protection in the healthcare environment.
With an eye on Europe, emphasis will be placed on the general framework of health policy in the European Union, with special mention of the Horizon Europe program with some practical cases and showing IDIVAL’s experience in this field.
Blended and cross-disciplinary training
The Master in Management and Administration of Health Services of the University of Cantabria (MADGS) is aimed at university graduates, graduates and university graduates, students in their final years, health professionals, as well as people interested in specializing in this professional field. It is also aimed at non-health professionals with an interest in this field.
The postgraduate course takes place between October 2023 and June 2024 and is compatible with the professional activity as it is blended learning. The face-to-face classes are held at the Faculty of Economics and Business Studies on Fridays (16:30 to 21:00 hours) and Saturdays (9:00 to 14:00 hours). Virtual classes are available through the Virtual Classroom Moodle of the University of Cantabria.
The complete master’s degree consists of seven modules plus the Final Project, although it is also possible to obtain the University Diploma of Specialization by taking only the last three modules plus the final project.
The modules are offered and can be taken individually and independently as Expert University Diplomas.
Modules and dates:
III. Public Management, Contracting and Competence Framework of Health Care Managers. 12/01/2024 to 10/02/2024
VII. Management of Health Services Provision. Primary Care Management and Hospital Management. 24/05/2024 to 07/06/2024
Final Program Work
Clinical trials, industrial property or human factor engineering will be key topics to be discussed with the students. The Valdecilla Health Research Institute (IDIVAL) participates in the Master’s Degree in Health Services Management of the University of Cantabria (UC), whose objective is to train professionals capable of leading processes of change and innovation in health […]
On the occasion of the World Day for Rare Diseases on February 29th, the Valdecilla Institute for Health Research (IDIVAL) will hold an event entitled ‘Update day on Rare Diseases and the need for a multiprofessional approach (360)´.
It will be a day where they will talk about rare diseases nowadays, the different treatments available and the perspectives to be taken into account such as rehabilitation, the expectations and aspirations of patients and the future vision of the Regional Ministry of Health of Cantabria.
It will take place in the Dr. Gómez Durán Assembly Hall of the Marqués de Valdecilla University Hospital. Admission will be free, although for logistical reasons it is suggested to send an e-mail before February 20 to enfraras360@gmail.com expressing interest in attending.
It is organized by José A. Riancho, Domingo González-Lamuño and José L. Fernández Luna, researchers from the Internal Medicine, Pediatrics and Genetics Services of HUMV and also IDIVAL researchers.
In addition, It has the collaboration of the companies Sanofi, Nutricia and Takeda.
On the occasion of the World Day for Rare Diseases on February 29th, the Valdecilla Institute for Health Research (IDIVAL) will hold an event entitled ‘Update day on Rare Diseases and the need for a multiprofessional approach (360)´. It will be a day where they will talk about rare diseases nowadays, the different treatments available […]
Previous hypertension, diabetes and renal insufficiency could alter plasma markers
A multidisciplinary research team belonging to the Neurodegenerative Diseases Group of IDIVAL and the Cognitive Impairment Unit of the Neurology Service of the Marqués de Valdecilla University Hospital (HUMV) has conducted a study aimed at understanding how different physiological variables and previous diseases could influence the early diagnosis of Alzheimer’s disease. The Clinical Analysis and Biochemistry Service and the Immunology Service of the HUMV have also collaborated in the research.
The research was carried out on 208 cognitively healthy volunteers from the Valdecilla Cohort by analyzing different markers in plasma and cerebrospinal fluid. This procedure is a simple, reliable and minimally invasive way to identify variables prior to observing the first memory failures characteristic of the disease.
The markers are two proteins called β-amyloid (forms β-40 and β-42), the ratio between them that biologically defines the disease and, finally, the protein called phosphorylated tau (p-tau181). In addition, these markers have been related to multiple variables such as blood pressure, liver enzymes, renal filtration or different cardiovascular risk factors.
Likewise, prior diagnosis of hypertension and diabetes may also have an effect on plasma amyloid and tau protein levels.
The aim is to understand the dynamics of plasma markers in the preclinical stages of Alzheimer’s disease with the intention of using them in the future as a population screening tool and to be able to look for preventive treatments. This is especially important now that the first disease-modifying drugs are in the process of being approved in Europe.
The study has been published in the prestigious International Journal of Molecular Sciences.
Reference: Martínez-Dubarbie, F.; Guerra-Ruiz, A.; López-García, S.; Irure-Ventura, J.; Lage, C.; Fernández-Matarrubia, M.; Pozueta-Cantudo, A.; García-Martínez, M.; Corrales-Pardo, A.; Bravo, M.; et al. Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals. Int. J. Mol. Sci. 2024, 25, 1481. https://doi.org/10.3390/ijms25031481
Previous hypertension, diabetes and renal insufficiency could alter plasma markers A multidisciplinary research team belonging to the Neurodegenerative Diseases Group of IDIVAL and the Cognitive Impairment Unit of the Neurology Service of the Marqués de Valdecilla University Hospital (HUMV) has conducted a study aimed at understanding how different physiological variables and previous diseases could influence […]
portal point to a high visibility of IDIVAL authors with more than 62,000 citations of articles published in the period 2018-2022. In this way, the Valdecilla brand exceeds 280,000 citations since its creation.
Of note in the period 2018-22 are the citations of papers published in the areas of Immunology (1,383 citations), Pharmacology (1,307 citations) and Oncology (1,134 citations) and as the origin of the citations Spain, United States, Italy and England.
The IDIVAL researchers most cited in the publications of this period have been:
|
Author |
Citations |
| Blanco Alonso, Ricardo (S. Reumatología, HUMV) | 3.535 |
| Durán Martínez, Ignacio (S. Oncología, HUMV) | 2.982 |
| Rodríguez Rodríguez, Eloy Manuel (S. Neurología, HUMV) | 1.941 |
| Rivera Herrero, Fernando (S. Oncología, HUMV) | 1.929 |
| Crespo García, Javier (S. Digestivo, HUMV) | 1.766 |
| Hernández Hernández, José Luís (S. Medicina Interna, HUMV) | 1.486 |
| López Hoyos, Marcos (S. Inmunología, HUMV) | 1.339 |
| Corrales Martínez, Alfonso Fernando (S. Reumatología, HUMV) | 1.088 |
| de la Torre Hernández, José María (S. Cardiología, HUMV) | 1.034 |
| Ocio San Miguel, Enrique María (S. Hematología, HUMV) | 973 |
The 5 articles published in this period 2018-2022 most cited have been collaborative studies conducted on patients, published in high impact journals:
portal point to a high visibility of IDIVAL authors with more than 62,000 citations of articles published in the period 2018-2022. In this way, the Valdecilla brand exceeds 280,000 citations since its creation. Of note in the period 2018-22 are the citations of papers published in the areas of Immunology (1,383 citations), Pharmacology (1,307 citations) […]
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
Meeting of the Ethics Committee for Research involving Medicines and Medical Devices
It will allow Cantabria to implement pilot initiatives to promote healthier environments and reduce social inequalities
The EU recently approved a proposal for a Joint Action for the prevention of Cancer and other Non Communicable Diseases (NCDs) with an amount of 75 million euros, which makes it a landmark initiative in public health. A project in which more than 20 EU member states participate together with Norway, the coordinating country, Iceland and Ukraine. Cantabria, Valencia, Catalonia and the Food Safety and Nutrition Agency of the Ministry of Health are the communities and entities participating on the Spanish side.
The aim of this Joint Action is to support strategies and policies designed to reduce the burden of cancer and other NCDs, diseases that constitute a large proportion of the total burden of disease in Europe, much of which can be prevented with appropriate policies.
The objectives of this initiative are:
– To improve the joint capacities of Member States to plan and implement policies and activities for the prevention of cancer and other NCDs at national, regional and local levels.
– Improve the data and monitoring system for cancer and other NCDs and their common risk factors.
– Contribute to the reduction of social inequalities in cancer and other NCDs.
– Engage and support key stakeholders in the field of cancer and NCD prevention, including decision makers at all levels of government, civil society organizations, professionals, the general population and patient groups to facilitate cooperation and joint efforts.
The IDIVAL Research Institute will lead the work on behalf of Cantabria, bringing together the participation of other health institutions, such as the Ministry of Health of the Government of Cantabria, the Cantabrian Health Service, the Marqués de Valdecilla University Hospital and others.
The IDIVAL Research Institute will lead the work on behalf of Cantabria, bringing together the participation of other health institutions, such as the Ministry of Health of the Government of Cantabria, the Cantabrian Health Service, the Marqués de Valdecilla University Hospital and others.
The region of Cantabria will receive around 850,000 € to develop several pilots within the work packages WP6 Healthy environments, WP7 on social inequalities and WP10 on identification of individuals at risk and will participate in the cross-cutting work packages of communication and dissemination and evaluation and sustainability.
Joint Action will have a duration of four years and will officially start in January 2024, followed by a kick-off meeting in February in Oslo, Norway. This initiative provides participating countries with a real impact on the development of public health policies in the EU and the strengthening of collaboration within the region.
It will allow Cantabria to implement pilot initiatives to promote healthier environments and reduce social inequalities The EU recently approved a proposal for a Joint Action for the prevention of Cancer and other Non Communicable Diseases (NCDs) with an amount of 75 million euros, which makes it a landmark initiative in public health. A […]
The results of the largest European prospective multicenter study on the surgical treatment of right colon cancer have been published.
The MIRCAST study, an International multicenter project led for the whole of Europe from the IDIVAL Institute, was born in 2018 with the aim of evaluating the different ways of performing intestinal anastomosis after minimally invasive right colectomy and to determine whether robotic instruments can contribute something in these procedures.
A minimally invasive approach is commonly used in right colectomy, and studies show a reduction in complications, blood loss and reduced hospital stay compared to an open approach. However, controversy remains as to whether robotic assistance is advantageous for this technique or not and whether an intracorporeal (ICA) or extracorporeal anastomosis (ECA) is better.
MIRCAST arose precisely with the aim of shedding light in this field and prospectively evaluating postoperative recovery, hospital stay, wound complications, severe complications and mid-term outcomes (hernia, recurrence …) of minimally invasive right colectomy, comparing intracorporeal with extracorporeal anastomosis and comparing conventional and robotic laparoscopic instruments.
For this purpose, a prospective, international, multicenter, 4-parallel cohort study was designed (robotic right colectomy with ACI, robotic right colectomy with RCT, laparoscopic right colectomy with ACI and laparoscopic right colectomy with RCT) in which 59 hospitals from 12 European countries participated. A total of 1,320 patients from all over Europe were included in the study.
Recently researchers from the MIRCAST Project have published in the British Journal of Surgery the results of the perioperative period revealing that there were no differences in the composite outcome of surgical wound infections and serious postoperative complications between intracorporeal versus extracorporeal anastomosis or laparoscopic versus robotic-assisted surgery. A significantly lower rate of complications was observed in the group of patients treated with AIC. The robotic approach had a significantly lower rate of postoperative ileus and a significantly higher number of resected nodes.
These results highlight the advantages for patients when managed by robotic minimally invasive surgery and AIC.
The MIRCAST study is still ongoing and is currently collecting mid-term data from patients who have already undergone surgery, which will allow us to see the impact on quality of life of the different techniques and the oncologic outcomes of the different approaches.
The results of the largest European prospective multicenter study on the surgical treatment of right colon cancer have been published. The MIRCAST study, an International multicenter project led for the whole of Europe from the IDIVAL Institute, was born in 2018 with the aim of evaluating the different ways of performing intestinal anastomosis after […]
